Valuation: ANI Pharmaceuticals, Inc.

Market Cap 1.53B 1.37B 1.28B 1.16B 2.19B 148B 2.2B 15.33B 5.98B 75.4B 5.75B 5.63B 242B P/E 2026 *
14.3x
P/E 2027 * 12.6x
Enterprise Value 1.68B 1.5B 1.4B 1.27B 2.4B 163B 2.42B 16.84B 6.57B 82.77B 6.32B 6.18B 266B EV / Sales 2026 *
1.53x
EV / Sales 2027 * 1.2x
Free-Float
86.75%
Yield 2026 *
-
Yield 2027 * -
1 day+0.57%
1 week-0.95%
Current month-0.99%
1 month+0.98%
3 months-15.43%
6 months-6.83%
Current year-8.88%
1 week 70.8
Extreme 70.8
73.96
1 month 69.58
Extreme 69.58
79.43
Current year 69.58
Extreme 69.58
87.76
1 year 69.58
Extreme 69.58
97
3 years 48.2
Extreme 48.2
99.5
5 years 22.31
Extreme 22.31
99.5
10 years 22.31
Extreme 22.31
99.5
Manager TitleAgeSince
Chief Executive Officer 48 2020-09-07
Director of Finance/CFO 55 2016-05-05
Compliance Officer - 2022-02-23
Director TitleAgeSince
Chairman 62 2025-11-23
Director/Board Member 68 2020-08-05
Director/Board Member 66 2020-08-05
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 Sell

Chief Financial Officer

-2,850 0.0124%
9/15/26 Sell

Chief Executive Officer

-5,400 0.0235%
9/14/26 Sell

General Counsel

-500 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+0.57%-0.95%-21.87%+23.19% 1.53B
+2.70%+0.35%+40.67%+110.31% 1,032B
+1.44%-3.41%+37.36%+63.95% 614B
+1.75%+3.07%+17.89%+83.05% 471B
+0.60%-4.35%+60.80%+37.46% 350B
+2.92%+3.06%+24.83%+45.10% 337B
+2.42%-0.74%+13.44%+35.80% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.60%-2.49%+40.45%+54.44% 218B
+1.82%-2.93%+29.29%+96.48% 179B
Average +1.72%-3.20%+23.82%+56.20% 371.64B
Weighted average by Cap. +1.83%-3.18%+32.14%+70.57%

Financials

2026 *2027 *
Net sales 1.1B 985M 918M 835M 1.57B 107B 1.59B 11.04B 4.31B 54.26B 4.14B 4.05B 174B 1.22B 1.09B 1.02B 925M 1.74B 118B 1.76B 12.22B 4.77B 60.1B 4.59B 4.49B 193B
Net income 111M 99.48M 92.72M 84.3M 159M 10.78B 160M 1.11B 435M 5.48B 418M 409M 17.6B 128M 114M 107M 96.9M 183M 12.39B 184M 1.28B 500M 6.3B 481M 470M 20.23B
Net Debt 150M 134M 125M 114M 214M 14.51B 216M 1.5B 586M 7.38B 563M 551M 23.7B -68.85M -61.5M -57.32M -52.12M -98.16M -6.66B -98.96M -689M -269M -3.39B -258M -253M -10.88B
Projected Income Statement - Annual - ANI Pharmaceuticals, Inc.
Logo ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Employees
970
Date Price Change Volume
26-10-07 US$71.93 +0.57% 437,596
26-10-06 US$71.52 -1.46% 292,000
26-10-05 US$72.58 +0.55% 346,867
26-10-02 US$72.18 -1.07% 309,509
26-10-01 US$72.96 +0.43% 316,691
Trader
Investor
Global
Quality
ESG MSCI
BB
Ratings Surperformance© - ANI Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
71.93USD
Average target price
105.78USD
Spread / Average Target
+47.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ANI Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ANIP Stock